Testing GSK5764227 combined with standard treatments in advanced solid tumors
Tests GSK5764227 alongside standard cancer treatments in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Key facts
- Where
- Barcelona, Madrid, and Málaga, SpainSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced adenocarcinoma of the colon or rectum (Cohort A) or of the prostate (Cohort B), who will get GSK5764227 together with standard treatments.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Cohort A: adenocarcinoma of the colon or rectum that cannot be removed by surgery, or that has spread (metastatic). Cohort B: adenocarcinoma of the prostate, confirmed by tissue or cell tests.
- Earlier treatment
- The record does not name required earlier treatment. Cannot have had immune-suppressing medicine within 30 days before the first dose. Low-dose prednisone (10 mg a day or less) or equivalent is allowed.
Main reasons for not taking part
- Another cancer that got worse or needed active treatment in the past 24 months (with some skin and in-situ exceptions)
- Major surgery within 28 days before the first dose
- Untreated brain or central nervous system metastases, or ones that have grown
- Current or past interstitial lung disease or pneumonitis needing high-dose glucocorticoids
- Autoimmune disease needing systemic treatment in the past 2 years
Read by machine on 12 November 2026.
Where in Spain
- BarcelonaHospital not named in the registryContact: Guzman Alonso Casal (principal investigator)Taking people
- MadridHospital not named in the registryContact: Teresa Alonso Gordoa (principal investigator)Taking people
- MálagaHospital not named in the registryContact: Javier García Corbacho (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- GlaxoSmithKline
- Trial code
- NCT07277270EU 2025-522274-37-00
- Record updated
- 25 September 2026
- Original description
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.Read full original descriptionShow less
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Inclusion: Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose; Has adequate organ function; Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A); Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B).
Exclusion: Has had any major surgery within 28 days prior to first dose; Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose; Has serious infection within 4 weeks prior to the first dose,; Any evidence of current interstitial lung disease (ILD) or pneumonitis OR a prior history of ILD requiring high-dose glucocorticoids or non-infectious pneumonitis requiring high-dose glucocorticoids; Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening; Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long-term [30 days or longer]). Low-dose corticosteroids (prednisone ≤10 milligrams (mg)/day or equivalent) may be administered; Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of disease; Has untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed.